1. Home
  2. ACET vs TAYD Comparison

ACET vs TAYD Comparison

Compare ACET & TAYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACET
  • TAYD
  • Stock Information
  • Founded
  • ACET 1947
  • TAYD 1955
  • Country
  • ACET United States
  • TAYD United States
  • Employees
  • ACET N/A
  • TAYD N/A
  • Industry
  • ACET Biotechnology: Pharmaceutical Preparations
  • TAYD Industrial Machinery/Components
  • Sector
  • ACET Health Care
  • TAYD Industrials
  • Exchange
  • ACET Nasdaq
  • TAYD Nasdaq
  • Market Cap
  • ACET 124.1M
  • TAYD 150.4M
  • IPO Year
  • ACET N/A
  • TAYD N/A
  • Fundamental
  • Price
  • ACET $1.48
  • TAYD $51.62
  • Analyst Decision
  • ACET Strong Buy
  • TAYD
  • Analyst Count
  • ACET 4
  • TAYD 0
  • Target Price
  • ACET $15.25
  • TAYD N/A
  • AVG Volume (30 Days)
  • ACET 445.1K
  • TAYD 20.5K
  • Earning Date
  • ACET 08-13-2024
  • TAYD 08-15-2024
  • Dividend Yield
  • ACET N/A
  • TAYD N/A
  • EPS Growth
  • ACET N/A
  • TAYD 45.76
  • EPS
  • ACET N/A
  • TAYD 2.58
  • Revenue
  • ACET N/A
  • TAYD $44,582,807.00
  • Revenue This Year
  • ACET N/A
  • TAYD N/A
  • Revenue Next Year
  • ACET N/A
  • TAYD N/A
  • P/E Ratio
  • ACET N/A
  • TAYD $20.01
  • Revenue Growth
  • ACET N/A
  • TAYD 10.90
  • 52 Week Low
  • ACET $1.05
  • TAYD $19.81
  • 52 Week High
  • ACET $3.77
  • TAYD $61.70
  • Technical
  • Relative Strength Index (RSI)
  • ACET 52.39
  • TAYD 50.18
  • Support Level
  • ACET $1.40
  • TAYD $53.06
  • Resistance Level
  • ACET $1.54
  • TAYD $57.25
  • Average True Range (ATR)
  • ACET 0.10
  • TAYD 2.69
  • MACD
  • ACET -0.00
  • TAYD 0.05
  • Stochastic Oscillator
  • ACET 36.00
  • TAYD 39.53

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About TAYD Taylor Devices Inc.

Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs and Vibration Dampers. In general, its products are used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its product to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.

Share on Social Networks: